EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates in NMOSD and MOGAD Diagnosis and Treatment

Laura Cacciaguerra, Eoin P Flanagan

Neurologic Clinics · 2024-02 · 42 (1) · 77-114

DOI: 10.1016/j.ncl.2023.06.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurologic Clinics, 2024-02. Verfasst von Laura Cacciaguerra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Central Nervous System Diseases. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are antibody-associated diseases targeting astrocytes and oligodendrocytes, respectively. Their recognition as distinct entities has led to each having its own diagnostic criteria that require a combination of clinical, serologic, and MRI features. The therapeutic approach to acute attacks in AQP4+NMOSD and MOGAD is similar. There is now class 1 evidence to support attack-prevention medications for AQP4+NMOSD. MOGAD lacks proven treatments although clinical trials are now underway. In this review, we will outline similarities and differences between AQP4+NMOSD and MOGAD in terms of diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaCentral Nervous System DiseasesHumansMyelin-Oligodendrocyte GlycoproteinImmunoglobulin GAutoantibodiesAquaporin 4Central Nervous System

Stichwörter der Autor:innen

AQP4-IgGDiagnosisMOGMOG-IgGTreatmentaquaporin-4myelin oligodendrocyte glycoproteinneuromyelitis optica spectrum disorder

Substanzen

Myelin-Oligodendrocyte GlycoproteinImmunoglobulin GAutoantibodiesAquaporin 4

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Flana…

Förderung

  • NINDS NIH HHS

Zitieren

APA

Cacciaguerra, L., & Flanagan, E. P. (2024). Updates in NMOSD and MOGAD Diagnosis and Treatment. Neurologic Clinics, 42(1), 77-114. https://doi.org/10.1016/j.ncl.2023.06.009

Vancouver

Cacciaguerra L, Flanagan EP. Updates in NMOSD and MOGAD Diagnosis and Treatment. Neurologic Clinics. 2024;42(1):77-114. doi:10.1016/j.ncl.2023.06.009

BibTeX
@article{Cacciaguerra2024,
  author = {Cacciaguerra, Laura and Flanagan, Eoin P},
  title = {Updates in NMOSD and MOGAD Diagnosis and Treatment},
  journal = {Neurologic Clinics},
  year = {2024},
  volume = {42},
  number = {1},
  pages = {77--114},
  doi = {10.1016/j.ncl.2023.06.009}
}
Kostenlos starten →